The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Investigation Continues on Repurposed Rheumatology Therapies for COVID-19 Cytokine Storm

Investigation Continues on Repurposed Rheumatology Therapies for COVID-19 Cytokine Storm

November 14, 2020 • By Ruth Jessen Hickman, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

ACR CONVERGENCE 2020—Part of a scientific session on Monday, Nov. 9, focused on the use of various rheumatology therapies as repurposed treatments for the atypical cytokine storm syndrome that occurs in some people with COVID-19. Roberto Caricchio, MD, chief of the Division of Rheumatology at Lewis Katz School of Medicine, Temple University, Philadelphia, spoke to ACR colleagues about the characteristics of this syndrome, the rationale behind therapeutic use of these treatments and what has been learned.

You Might Also Like
  • Don’t Forget the Host: COVID-19 Cytokine Storm
  • Rheumatology Biologic Expertise Valued for COVID-19 Treatment Decisions
  • Oxford University to Study Adalimumab as Potential COVID-19 Treatment
Explore This Issue
December 2020
Also By This Author
  • A Historical Look at the Characterization of Lupus as a Systemic Disease

Of the numerous clinical trials now taking place for COVID-19, a significant subset are for therapies sometimes used in rheumatology: small-molecule, disease-modifying anti-rheumatic drugs, such as baricitinib; and biologics, such as those blocking interleukin 1 (IL-1) and IL-6. For the most part, these therapies have been selected not for antiviral properties, but for their potential capacity to calm cytokine storm syndrome secondary to COVID-19. Dr. Caricchio explained, “The rationale for using [them] is solid because of the demonstrations we have seen many times over the past several months of an overly exuberant immune response.”

Roberto Caricchio, MD

Dr. Caricchio is the principal investigator for several clinical trials related to COVID-19, including one sponsored by Eli Lilly for the JAK1/JAK2 inhibitor baricitinib and a trial with Swedish Orphan Biovitrum studying the anti-interferon gamma antibody emapalumab and the IL-1 antagonist anakinra. He and other colleagues with expertise in cytokine storm published a paper in early April regarding its immunopathology in the context of COVID-19.1 “We thought that—given the data from Europe and from China—there was certainly a hyperinflammatory response ongoing,” he related.

Cytokine Storm Differences
Cytokine storm represents a family of related syndromes with some overlapping pathophysiological signals and some important differences. It can occur due to infectious diseases, such as COVID-19 or influenza; malignancy; chimeric antigen receptor T cell therapy (CAR-T therapy), or from such genetic syndromes as hemophagocytic lymphohistiocytosis (HLH). It can also occur from macrophage activation syndrome (MAS), as a sequela of systemic juvenile idiopathic arthritis or other autoimmune disease. In all cases, uncontrolled immune activation leads to excessive release of multiple cytokines, leading to hyperinflammation and severe multi-organ disease.1

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Because of differences in the somewhat atypical cytokine storm seen in COVID-19, Dr. Caricchio et al. proposed a new set of predictive criteria for cytokine storm somewhat distinctive from the criteria that have been used in HLH and MAS.2 Unlike in some other forms, cytokine storm secondary to COVID-19 usually manifests with lymphopenia only—and not with two or more cytopenias. Unlike these other forms, organomegaly is uncommon, and in fact the syndrome can cause shrunken lymph nodes and spleen.

Pages: 1 2 3 | Single Page

Filed Under: ACR Convergence, Meeting Reports Tagged With: ACR Convergence 2020, COVID-19Issue: December 2020

You Might Also Like:
  • Don’t Forget the Host: COVID-19 Cytokine Storm
  • Rheumatology Biologic Expertise Valued for COVID-19 Treatment Decisions
  • Oxford University to Study Adalimumab as Potential COVID-19 Treatment
  • Research on IL-17 Cytokine May Lead to Novel Therapies for RA

About Ruth Jessen Hickman, MD

Ruth Jessen Hickman, MD, was born and raised in eastern Kentucky, where she first cultivated her love of literature, writing and personal narratives. She attended Kenyon college, where she received a Bachelor of Arts in philosophy, summa cum laude. She worked with individuals with psychiatric conditions and later in a neuroscience lab at the University of Illinois, Chicago, before graduating from Indiana University Medical School in 2011. Instead of pursuing clinical medicine, Ruth opted to build on her strength of clearly explaining medical topics though a career as a freelance medical writer, writing both for lay people and for health professionals. She writes across the biomedical sciences, but holds strong interests in rheumatology, neurology, autoimmune diseases, genetics, and the intersection of broader social, cultural and emotional contexts with biomedical topics. Ruth now lives in Bloomington, Ind., with her husband, son and cat. She can be contacted via her website at ruthjessenhickman.com.

View more by this author»

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)